NG Bio, an early-stage investor and venture builder addressing the harmful immune responses, such as inflammation, that cause or exacerbate many of the major human diseases. By tackling these, we extend human health span and longevity.
As scientists continue to unlock the secrets to the drivers of inflammation, NG Bio is creating the next generation of medicines and diagnostics in the breakthrough areas of cure, personalisation, regeneration, and women’s health.
We partner with world leading entrepreneurs, research institutions and academic institutions across the globe to realise our vision of life with control over chronic diseases.
Company Details
- Employees
- 15
- Founded
- -
- Address
- London, Gb
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- ngvc.co.uk
- Keywords
- Autoimmune and Chronic Inflammatory Diseases, Drug Development, Therapeutic Venture Builder, Immunology, Investor, Early stage investment, Biotechnology, Life sciences.
- HQ
- London
Ng Bio Questions
Ng Bio's website is ngvc.co.uk
Ng Bio's LinkedIn profile is https://uk.linkedin.com/company/ngbioo
Ng Bio has
15 employees.
View email and phone details for 15
employees at Ng Bio.
Ng Bio's industry is
Venture Capital and Private Equity Principals
Ng Bio's top competitors are
Mesenbio,
Crick Science Entrepreneur Network (Csen),
Piccadilly Prime Ltd.,
One Rosemond,
Dsw Ventures,
Kerna Ventures,
Lightox Ltd,
Cellesce Ltd,
Abselion,
Alma Angels.
Ng Bio's categories are Venture Capital and Private Equity Principals
Ng Bio's founding year is 2020
